semaglutide moa weight loss Mechanism of action (MOA) of tirzepatide tirzepatide moa weight loss Semaglutide

The glucagon peptide family [glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon] Figure 2: Simplified schematic overview of the glucagon superfamily of peptides [28] The glucagon peptide family members [GLP-1, GIP and glucagon] have similar peptide sequences, permitting the development of single-sequence multi-receptor agonists [4]

These drugs work by mimicking a naturally occurring hormone that regulates blood glucose levels and appetite

The STEP trials show that continuing Wegovy maintains weight loss, while stopping leads to a regain of around two-thirds of the weight lost within a year

Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is launching the Medicare GLP-1 Bridge, a short-term program that gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight loss medications for a $50 copay per month

Magoulas PL, El-Hattab AW

Other Reported Adverse Effects In addition to gastrointestinal issues and thyroid-related risks, semaglutide may cause other side effects, including: Fatigue and Dizziness : Some individuals report feeling unusually tired or dizzy while taking semaglutide